Otsuka America launches new unit focused on digital therapeutics, AI and mental health

By SharpBrains | June 10, 2024

Otsu­ka defies dig­i­tal health down­turn with new com­pa­ny (MedTech­Dive): Otsu­ka Amer­i­ca, a sub­sidiary of the Japan­ese drug and device mak­er, this month launched a new com­pa­ny focused on dig­i­tal health. The firm, called Otsu­ka Pre­ci­sion Health, will roll out its first prod­uct this sum­mer, a pre­scrip­tion dig­i­tal ther­a­peu­tic for major depres­sive dis­or­der. San­ket Shah, who…

Read More

The Do’s and Don’ts of Harnessing Technology (and Anxiety) for Good

By SharpBrains | February 28, 2022

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing impor­tant brain & men­tal health news plus a few fun brain teasers to test your rea­son­ing skills and more… #1. Chal­lenge ahead: Har­ness­ing tech­nol­o­gy for good men­tal health “Tech­nol­o­gy can not only help us grow out of unhealthy habits, it is also pos­si­ble to expand human mental…

Read More

Otsuka and Virtual Reality start-up Jolly Good sign $43M deal to promote Social Skills Training (SST) therapies, helping schizophrenia patients first

By SharpBrains | February 2, 2022

Otsu­ka signs on Jol­ly Good for $43M men­tal health VR deal (Fierce Biotech): The duo will build out software—hosted on Jol­ly Good’s VR gog­gles and con­nect­ed tablet devices, and backed by Otsuka’s exper­tise in devel­op­ing neu­ro­log­i­cal therapeutics—that takes a social skills train­ing (SST) approach to treat­ing men­tal ill­ness. SST is a behav­ioral ther­a­py in which…

Read More

Click Therapeutics raises further $52M to build up digital therapeutics pipeline for depression, insomnia, smoking cessation and more

By SharpBrains | November 4, 2021

With Sanofi still on board, Click Ther­a­peu­tics clos­es $52M series B for dig­i­tal ther­a­peu­tics in depres­sion, chron­ic pain and more (Fierce Biotech): Anoth­er medtech devel­op­er’s plans to cre­ate dig­i­tal ther­a­peu­tics to treat a wide range of ill­ness­es are click­ing into place, thanks to a third mul­ti­mil­lion-dol­lar invest­ment in Click Ther­a­peu­tics in bare­ly a year.

Read More

Innovation in COVID times: Otsuka and Click Therapeutics announce fully virtual clinical trial, leveraging Verily’s Project Baseline

By SharpBrains | March 19, 2021

Otsu­ka launch­es piv­otal tri­al of dig­i­tal ther­a­peu­tics for depres­sion (Med­C­i­ty News): Otsu­ka Phar­ma­ceu­ti­cal is launch­ing a vir­tu­al study to see if dig­i­tal ther­a­peu­tics can reduce depres­sion symp­toms. It’s the next step in a part­ner­ship between the Tokyo-based drug­mak­er and Click Ther­a­peu­tics, a dig­i­tal health start­up that is devel­op­ing pro­grams for smok­ing ces­sa­tion, depres­sion and insomnia.

Read More

Otsuka Pharma and Click Therapeutics enter partnership poised to transform mental healthcare

By SharpBrains | January 4, 2019

Otsu­ka, Click Ther­a­peu­tics part­ner to cre­ate ther­a­py for men­tal ill­ness (Ver­dict Med­ical Devices): “Otsu­ka Pharmaceutical’s US divi­sion Otsu­ka Amer­i­ca has part­nered with Click Ther­a­peu­tics to devel­op and com­mer­cialise a pre­scrip­tion dig­i­tal ther­a­peu­tic for treat­ing major depres­sive dis­or­der (MDD)

Read More